Epigenetic Age Acceleration of Stomach Adenocarcinoma Associated With Tumor Stemness Features, Immunoactivation, and Favorable Prognosis

Chunhong Hong1†, Shaohua Yang1†, Qiaojin Wang2, Shiqiang Zhang3, Wenhui Wu1, Jinyao Chen1, Danhui Zhong3, Mingze Li1, Liang Li1, Jianfeng Li1, Hong Yu1, Hong Chen1, Qianlin Zeng1 and Changhua Zhang1*

1Center of Digestive Disease, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China, 2Department of Surgical Intensive Care Unit, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, 3Department of Urology, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China, 4Department of Physiotherapy, The University of Hongkong-Shenzhen Hospital, Shenzhen, China

Background: Abnormal DNA methylation (DNAm) age has been assumed to be an indicator for canceration and all-cause mortality. However, associations between DNAm age and molecular features of stomach adenocarcinoma (STAD), and its prognosis have not been systematically studied.

Method: We calculated the DNAm age of 591 STAD samples and 115 normal stomach samples from The Cancer Genome Atlas (TCGA) and gene expression omnibus (GEO) database using the Horvath’s clock model. Meanwhile, we utilized survival analysis to evaluate the prognostic value of DNAm age and epigenetic age acceleration shift. In addition, we performed weighted gene co-expression network analysis (WGCNA) to identify DNAm age-associated gene modules and pathways. Finally, the association between DNAm age and molecular features was performed by correlation analysis.

Results: DNA methylation age was significantly correlated with chronological age in normal gastric tissues (r = 0.85, p < 0.0001), but it was not associated with chronological age in STAD samples (r = 0.060, p = 0.2369). Compared with tumor adjacent normal tissue, the DNAm age of STAD tissues was significantly decreased. Meanwhile, chronological age in STAD samples was higher than its DNAm age. Both DNAm age and epigenetic acceleration shift were associated with the prognosis of STAD patients. By using correlation analysis, we also found that DNAm age was associated with immunoactivation and stemness in STAD samples.

Conclusion: In summary, epigenetic age acceleration of STAD was associated with tumor stemness, immunoactivation, and favorable prognosis.

Keywords: DNA methylation age, stomach adenocarcinoma, prognosis, immunoactivation, tumor stemness
INTRODUCTION

Gastric cancer (GC) is one of the most common gastrointestinal tract malignancy and it is also the leading causes of cancer-related mortality worldwide (Van Cutsem et al., 2016; Siegel et al., 2018; Sitarz et al., 2018). Stomach adenocarcinoma (STAD) comprises 95% of gastric cancer, which primarily arises from gastric epithelium including gastric mucosa and superficial glands of the epithelium (Schwartz, 1996; Dicken et al., 2005). Immune microenvironment in STAD has been increasingly studied in recent years (Couderc et al., 1987; Leone et al., 2017; Patil et al., 2018; Jiang et al., 2019; Li et al., 2019; Zeng et al., 2019). In addition, immune cell infiltration, such as T helper (Th), Th2, and mast cells, has been reportedly related to the prognosis of STAD patients (Wang et al., 2020).

Epigenetic clock or DNA methylation (DNAm) age was found to be highly correlated with chronological age (CA) in most tissues and cell types in human (Horvath, 2013, 2015). Generally speaking, DNAm age in different tissues and cell types shared the following characteristics: first, the DNAm age of embryonic and induced pluripotent stem (iPS) cells was close to zero; second, DNAm age was correlated with the number of cell passages; and third, DNAm age caused a highly heritable measure of chronological age acceleration (Horvath, 2013). Vertical shift between DNAm age and CA, or epigenetic acceleration shift, has been reported to be closely associated with many cancer types, including cervical, breast, and lung cancer (Levine et al., 2015; Ambatipudi et al., 2017; Lu et al., 2020). A recent study found that DNAm age was significantly associated with CA in normal cervical tissues and cervical squamous cell carcinoma (CSCC) samples. In addition, DNAm age acceleration of CSCC leads to immunoactivation, human papillomavirus 16/18 expression, and better prognosis (Lu et al., 2020). Interestingly, prognostic effects of DNAm age acceleration in breast carcinoma show opposite conclusions in two studies (Ren et al., 2018; Kresovich et al., 2019). One of them stated that DNAm age acceleration was significantly associated with oncogenesis in breast cancer (Kresovich et al., 2019). However, the other argued that DNAm age acceleration was significantly associated with better prognosis after adjusting for clinicopathological variables, such as estrogen receptor status and cancer stage (Ren et al., 2018). The possible reasons for the discrepancies between them are as follows: (i) the clinical samples used in the two studies were different. In Kresovich et al.’s research, DNAm age for each breast cancer patients were calculated based on blood samples. On the other hand, DNAm age for each breast cancer patients in Ren et al.’s paper was calculated based on cancer tissue samples; (ii) the outcome indicators of the two studies were different. In Kresovich et al.’s study, the outcome indicator was the occurrence of breast cancer during the 5-year observation period. On the other hand, the outcome indicators of Ren et al.’s study were the prognosis and recurrence of breast cancer patients; and (iii) the variables included in the two studies are different, which may have an impact on the model. Taken together, these studies indicated a new perspective on the pathogenesis and prognostic biomarker of cancer.

Although epigenetic age shift in some studies has been assumed to be an indicator for canceration and all-cause mortality, the DNAm age in STAD and its clinical value remains poorly understood. In this study, we focused on STAD and systematically analyzed associations of epigenetic age with molecular characteristics and clinical outcomes in STAD patients. Briefly, the correlation between DNAm age and CA in STAD samples was impaired, and epigenetic acceleration shift was associated with a favorable prognosis in STAD patients. In addition, DNAm age was associated with immunoactivation and tumor stemness features in STAD samples.

MATERIALS AND METHODS

Data Acquisition From the TCGA and GEO Database

Both 27 K and 450 K array data from Illumina Infinium platform can be used to calculate epigenetic age based on a Horvath’s clock model (Horvath, 2013). We therefore downloaded human-methylation 450 K array data of STAD patients including 388 STAD and two tumor adjacent normal tissues from the Santa Cruz Xena Public Data Hubs of the University of California.1 Corresponding clinical information of STAD samples was obtained from Cruz Xena Public Data Hubs and cBioPortal website.2 Due to the limitation samples size of normal gastric tissue, another 115 normal gastric samples were obtained from gene expression omnibus (GEO) online database.3 Both GSE92863 (Yamashita et al., 2019; 16 normal gastric samples) and GSE76641 (Roost et al., 2017; five normal gastric samples) datasets based on Illumina human-methylation 450 K array data which contains age information. However, GSE30601 (Zouridis et al., 2012) dataset which contained 203 gastric cancer and 94 tumor adjacent normal tissues based on Illumina human-methylation 27 K array data without detailed age information. We, therefore, used GSE30601 dataset to compare the DNAm age difference between STAD and its corresponding paired tumor adjacent normal samples. The mRNA expression profile of 375 STAD and 32 tumor adjacent normal tissues were downloaded from The Cancer Genome Atlas (TCGA) database (https://portal.gdc.cancer.gov/repository). The RNA-SEQ data were quantified as raw read count for differential expression gene (DEG) analysis. RNA-SEQ counts data of STAD samples were transferred into transcripts per kilobase million (TPM) values, and were then used to calculate immune cells infiltration profiles and tumor stemness features. Figure 1 illustrates the protocol of bioinformatics analyses.

DNA Methylation Age and Epigenetic Age Shift

DNA methylation age was calculated by the Horvath’s clock model based on methylation β value matrix. The β values for
each site were calculated by the following equation: $\beta = \frac{\text{Mean}_m\text{ethylated (M)}}{\text{Mean}_m\text{ethylated (M) + Unmethylated (U)}}$. Function to calculate DNAm age in the Horvath’s clock model was obtained from Horvath’s article (Horvath, 2013) and performed in R software (version 3.5.1). Mathematics of DNAm age calculation function in the Horvath’s clock model is briefly described as follows:

$$\text{DNAmage} = \text{inverse.F}(b_0 + b_1\text{CpG}_1 + \ldots + b_{353}\text{CpG}_{353}).$$

$F$ is a function used for age transformation and $353 b_i$ coefficients were obtained from elastic net regression results in a linear regression model. Vertical shift (i.e., acceleration) of epigenetic age was calculated by the formula $E\text{-value} = \text{DNAmage}_n - \text{CA}_n$ where $\text{CA}_n$ is the chronological age of each STAD sample. We therefore divided the STAD samples into epigenetic age accelerated (DNAmAge-ACC, $E\text{-value} > 0$) and epigenetic age decelerated group (DNAmAge-DEC, $E\text{-value} < 0$).

### Differential Methylated Probes and Motif Enrichment Analysis

Stomach adenocarcinoma methylation array data obtained from Cruz Xena Public Data Hubs was primarily presented as a $\beta$ value matrix. Firstly, we filtered and normalized this $\beta$ value matrix by using SWAN method embedded in ChAMP package (version 2.13.5). Then, differential methylated probes (DMPs) between DNAmAge-ACC and DNAmAge-DEC group were identified by the champ.DMP () function with the parameters adjusted $p < 0.05$ and delta $\beta > 0.1$. In addition, gene set enrichment analysis (GSEA) based on DMPs was performed by champ.GSEA () function in ChAMP package. ChAMP used pathway information downloaded from MSigDB. Then Fisher Exact Test will be used to calculate the enrichment status of each pathway. After gene enrichment analysis, champ.GSEA () function would automatically return pathways with value of $p$ smaller than adjPval cutoff. Finally, get.enriched.motif () in Enhancer Linking by Methylation/Expression Relationships (ELMER) package was used to find motif occurrences in differential methylated positions. Fisher’s and Benjamini-Hochberg test were performed to correct the background of all DMPs regions. According to the default parameters of the get.enriched.motif (), the motif occurred frequency $> 10$ times and 95% confidence interval of the odds ratio value $> 1.1$ was considered as significant motif.

### DEG and Function Annotation Analysis

Differential expression genes between STAD and tumor adjacent normal tissues obtained from TCGA online database were identified by edgeR packages in R software. In addition, we also used edgeR function to screen the DEGs DNAmAge-ACC and DNAmAge-DEC group. In this section, an adjusted $p < 0.05$ and fold change $> 2.0$ were considered as statistically significant. To investigate the potential mechanism of epigenetic age shift in canceration and prognosis of STAD, enrichment function annotation analysis was performed based on DEGs by using the org.Hs.eg.db and ClusterProfiler package (Yu et al., 2012) in R software and an adjusted $p < 0.05$ was considered as statistically significant. In addition, single gene GSEA was performed based on the median transcripts per million (TPM) value of each TF, STAD samples were divided into high and low expression groups. Then, GSEA analysis was performed.
to identify pathway enriched between TF high and low expression groups. In addition, permutation test was performed to calculate value of \( p \) in single gene GSEA analysis (Yu et al., 2012). Reference gene-set (c2.cp.kegg.v6.2.symbols.gmt) was downloaded from MSigDB gene set hub and a value of \( p \) less than 0.01 was considered as statistically significant.

**Weight Gene Co-expression Network Analysis**

In order to further study the relationship between gene transcripts and DNAm age in STAD, we, therefore, further used gene co-expression network analysis to identify DNAm age-associated gene modules and pathways. Weight gene co-expression network analysis (WGCNA) was performed through the WGCNA package in R software as previously described (Zheng et al., 2019). Briefly, a pairwise coefficient matrix was first calculated by using correlation analysis (Pearson) and further converted into an adjacency matrix (weighted) based on a soft threshold. Then, a topological overlap matrix (TOM) was computed using blockwiseModules() function in WGCNA package based on the previous adjacency matrix. Hierarchical clustering and dynamic tree cut algorithm in WGCNA package were used to identify gene modules. In addition, module eigengene (ME) was considered as a summary value of gene expression profiles for the given gene module. Finally, correlation analysis (Pearson) was performed to calculate the correlation coefficient between ME and external DNAm age value.

**Immune Cells Infiltration Profile and Tumor Stemness Features Analysis**

We performed xCell algorithm-based on single-sample gene set enrichment analysis (ssGSEA) in R software to compute the enrichment score of 64 immune and stromal cell types in STAD samples (Aran et al., 2017). Briefly, enrichment score of 64 cell types are estimated by 489 gene signatures, and the primary enrichment score of all gene signatures corresponding to target cell type are averaged. Then, a cell matrix was generated including 34 types of immune cells and 30 types of other cells of each STAD sample. Immune cells can be further classified into nine categories, including CD8 T-cell subpopulations, CD4 T-cell subpopulations, gamma delta T cells (Tgd cells), B-cell subpopulations, monocyte/macrophage subpopulations, dendritic cell (DC) subpopulations, granulocyte subpopulations, nature killer (NK) cells, and NKT cells subpopulations. In addition, three summary score including immune-score, stroma-score, and microenvironment-score were also calculated for further analyses. One-class logistic regression (OCLR) machine-learning method based on pluripotent stem cell samples dataset was used to calculate the mRNA stemness index (mRNAsi) in STAD samples (Salomonis et al., 2016; Daily et al., 2017; Malta et al., 2018). The detail method to compute mRNAsi has been well noted in Malta’s paper (Malta et al., 2018) and is available on https://bioinformaticsfmrp.github.io/PanCanStem_Web/. According to OCLR algorithm, the mRNAsi of each sample was mapped to range 0–1 via utilizing a linear transformation model that subtracted the minimum value and divided by the maximum value.

**Statistical Analysis**

In this study, continuous variables were described as mean and SD, or median and quartiles (Q), depending on the value distribution of each variable which was tested by the Shapiro-Wilk test. Categorical code variables were reported as frequencies and proportions. The statistical analysis used to compare the difference between DNAmAge-ACC and DNAmAge-DEC groups included two independent samples t-test and paired samples t-test for mean values, Mann-Whitney U-test for median values, and Fisher’s exact test for frequencies and proportions variables. The correlation between two continuous variables was tested by Pearson (\( R \)) and Spearman (Rho) coefficients based on data distribution. In addition, the difference between two correlation coefficients was tested by Z-statistic. The prognostic value of DNAm age (or epigenetic age acceleration shift), transcription factors (TFs), immune cells, and mRNAsi were evaluated by Kaplan-Meier curve and univariate Cox regression model in R software (survival package). In this study, all statistical tests were performed in R software (version 3.5.1; Microsoft, Redmond, WA, United States) and a \( p < 0.05 \) (two-tailed) was served as a statistically significant level.

**RESULTS**

**Correlation Between Epigenetic and Chronological Age in Stomach Adenocarcinoma and Para-Cancer Tissues**

DNA methylation age was significantly correlated with CA in normal gastric tissues (\( r = 0.85, p < 0.0001, n = 23 \)), but it was not associated with CA in STAD samples (\( r = 0.060, p = 0.2369, n = 388 \); Figure 2A), which indicated that the epigenetic pattern observed in normal gastric tissues was disrupted in STAD samples. In normal gastric tissues, there was no difference between DNAm age and CA (\( p = 0.2826; \) paired samples t-test; Supplementary Figure 1); Meanwhile, CA in STAD samples were higher than DNAm age (\( p < 0.0001; \) paired samples t-test; Figure 2B). In addition, compared with para-cancer tissues, the DNAm age in STAD tissues was significantly decreased (\( p = 0.0011; \) independent samples t-test; Figure 2C). These results indicated that DNAm age deceleration may play an important role in tumorigenesis of STAD.

**Association Between Epigenetic Age Shift and Prognosis**

We then studied whether DNAm age was associated with the prognosis of STAD patients and found that higher DNAm age was associated with better overall survival (OS; \( p = 0.038 \)) according to Kaplan-Meier survival log-rank test (Supplementary Figure 1B). In addition, higher DNAm age acceleration value was associated with better disease-specific survival (DSS) event when using median and quartile acceleration value, respectively, (\( p = 0.031 \) and \( p = 0.049 \); Supplementary Figures 1G,K). To further study the
In this study, 318 STAD patients were identified as DNAmAge-DEC group, while only 70 patients were identified as DNAmAge-ACC group (Figure 3A; Table 1). In addition, most STAD samples in DNAmAge-ACC group showed higher mean methylation level, while most samples in DNAmAge-DEC group showed lower mean methylation level (Figure 3A). These results suggested that STAD patients in TCGA cohort include two clusters: DNAmAge-ACC cluster (low proportion; Figure 3A) and DNAmAge-DEC (high proportion; Figure 3A). We then studied whether this classification pattern was related to STAD patients’ prognosis, and found that DNAmAge-ACC was associated with favorable OS and DSS (p = 0.0088 and p = 0.042, respectively; Figures 3B, C).

Molecular Features Between DNAmAge-ACC and DNAmAge-DEC Group

Except for age, the distribution of patients’ clinical stage, fraction genome altered, mutation count, race, sex, neoplasm status, and survival event showed no significant difference between DNAmAge-DEC and DNAmAge-ACC groups (Table 1), which indicated that the demographical and clinicopathological characteristics of DNAmAge-DEC and DNAmAge-ACC groups were consistent and reasonable for use in addition to molecular analyses. We then used champ.DMP () and champ.DMR () function in R software to screen the DMPs and DMRs between DNAmAge-DEC and DNAmAge-ACC group. In this study, we identified 77,186 DMPs (p < 0.05 and |delta β| > 0.1) and 2008 DMRs (p < 0.05) in the samples including 70 DNAmAge-ACC and 318 DNAmAge-DEC samples (Figure 4A). Meanwhile, genome location analysis based on human methylation 450 bead-chip annotation platform showed that the gene body and intergenic region shared the highest proportion of DMPs, 31.6 and 26.3%, respectively (Figure 4A). Most DMPs (94.96%) between DNAmAge-ACC and DNAmAge-DEC group were identified as hypermethylation DMPs which are highly consistent with the Horvath’s clock model and clusters pattern (Figure 4A). We then performed GSEA to study the biological functions of DMPs in STAD patients and found that those CpG sites were significantly enriched in immune, tumor protein p53 (TP53), vascular endothelial growth factor A (VEGFA), and hypoxia-associated pathways (Figure 4B). To further study the effect of DMPs on mRNA transcripational phenotype, we then performed DEGs analysis between DNAmAge-ACC and DNAmAge-DEC groups and found that those DEGs were also significantly enriched in immune-associated pathways (Supplementary Figures 2A–D). In addition, 93.1% (1,659/1782) of the genes in DEGs were low expression (fold change < 0; Supplementary Figure 2E), which is highly consistent with DMPs between DNAmAge-ACC and DNAmAge-DEC groups.

Enriched Motifs of Differentially Methylated Sites

To further study the regulation mechanism of epigenetic age shift in STAD, we performed motif enrichment analysis based on ELMER package and identified 366 significantly enriched motifs in different methylation sites (p < 0.05 and odds ratio value > 1.1; Supplementary Table S1). We next sought to determine the expression profiles and prognosis effect of enriched motifs-associated TFs in TCGA STAD cohort. The expression level of the candidate genes was used to hierarchical clustering analysis. As showed in Figure 5A, candidate genes were divided into three clusters. In addition, enriched motifs and related TFs in three independent cluster such as activating transcription factor 4 (ATF4), LIM homeobox transcription factor 1 alpha (LMX1A), ZFP42 zinc finger protein (ZFP42), oligodendrocyte transcription factor 3 (Olig3), SRY-Box transcription factor 5...
(SOX5), LIM homeobox transcription factor 1 beta (LMX1B), SRY-Box transcription factor 21 (SOX21), iroquois homeobox 3 (IRX3), SRY-Box transcription factor 7 (SOX7), PBX homeobox 1 (PBX1), BARX homeobox 1 (BARX1), MAF BZIP transcription factor (MAF), RUNX family transcription factor 1 (RUNX1), HMG-Box transcription factor 1 (HBP1), SRY-Box transcription factor 2 (SOX2), and TEA domain transcription factor 3 (TEAD3) were related to the prognosis of STAD patients. These prognosis-associated TFs were also identified as DEGs between DNAmAge-ACC and DNAmAge-DEC groups as well as between cancer and tumor adjacent normal tissues (Figure 5A). In addition, some of these TFs such as ATF4, PBX1, and RUNX1 were significantly enriched in immune, epithelial mesenchymal transition (EMT), Wingless-type (Wnt), and Notch signaling associated pathway (Figure 5B).

Epigenetic Age Associated Gene Modules in TCGA STAD Cohort
Using WGCNA algorithm, we identified 90 co-expressed gene modules in TCGA STAD cohort (Figure 6A) based on a threshold value of 6 (Supplementary Figure 3). We then performed Pearson correlation analysis to calculate the coefficients between each genes module and DNAm age. Eight gene modules were positively correlated with the DNAm age of STAD patients ($p < 0.05$; Figure 6B). On the other hand, 21 gene modules were negatively correlated with DNAm age in STAD patients ($p < 0.05$; Figure 6B). In addition, we performed gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis to study the biological functions of genes in top two DNAm-age associated gene modules (saddlebrown and lightgreen) and found that these genes were significantly enriched in immune related pathways including antigen processing and presentation, Th1 and Th2 cell differentiation, Th17 cell differentiation, natural killer cell mediated cytotoxicity, and toll-like receptor signaling pathways (Figures 6C,D; Supplementary Figures 4A–F).

Epigenetic Age Shift and Immunophenotype
Enrichment analysis based on DEGs and WGCNA uncovered that epigenetic age shift was closely related to immune associated signaling and pathways in STAD patients. We then performed correlation analysis and found that DNAm age in TCGA STAD patients was significantly positively related to the infiltration
intensity of CD8 T cell, CD8 effective memory T cell (CD8 Tem), CD8 central memory T cell (CD8 Tcm), Tgd cell, CD4 memory T cell, CD4 Tem, Th2 cell, Th1 cell, macrophage, M1 macrophage, M2 macrophage, mast cell, and memory B cell (Figure 7A). We also found some DNAm age-associated immune cells including Tgd cell, Mast cell, Th2 cell, Th1 cell, and immune score are related to the prognosis of STAD patients (Figure 7A). In addition, the immune score, Th1 cell, Th2 cell, Tgd cell, and mast cell in DNAmAge-ACC group were significantly higher than DNAmAge-DEC group (Figures 7B–D; Supplementary Figure 5), which indicated that epigenetic age acceleration in STAD patients presented an immune-active pattern.

Epigenetic Age Shift and Tumor Stemness Features
DNA methylation age of embryonic and iPS cells was close to zero (Horvath, 2013), which indicated that epigenetic age shift may be related to the stemness feature of cancer. In addition, our GSEA results based on enriched motif-associated TFs showed that RUNX1 (TFs) in TCGA STAD cohort was significantly enriched in stem cells related pathway including Wnt and Notch signaling pathway (Figure 5B). We next sought to determine the relationship between DNAm age and stemness feature (mRNAsi) in TCGA STAD cohort. As showed in Figure 8A, in TCGA STAD patients, mRNAsi value was significantly positively correlated with DNAm age (N = 364, r = 0.1309, p = 0.0124). Interestingly, mRNAsi in DNAmAge-ACC group was significantly positively correlated with DNAm age (N = 50, r = 0.3155, p = 0.0256), but mRNAsi was not associated with DNAm age in DNAmAge-DEC patients (N = 314, r = −0.0009, p = 0.9865). In addition, compared with DNAmAge-DEC group, the mRNAsi in DNAmAge-ACC group was significantly increased (p = 0.012; independent samples t-test; Figure 8B). We also found that mRNAsi was related to the prognosis of STAD patients, including OS (p = 0.0015), DSS (p = 0.015), disease-free interval event (DFI, p = 0.013), and progression-free interval event (PFI, p = 0.01; Figures 8C–F).

DISCUSSION
An increasing number of studies suggest that DNAm age shift is a promising biomarker for studying aging associated diseases and cancer (Horvath, 2013; Zheng et al., 2016; Gao et al., 2018; Hofstatter et al., 2018; Rezwan et al., 2020; Sibbett et al., 2020). GC continues to be one of the leading causes of cancer-related death over the past 30 years (Dicken et al., 2005). We, therefore, focused on STAD and systematically analyzed

### TABLE 1 | Demographic and clinicopathological characteristic between DNA methylation (DNAm) age accelerated group (ACC) and DNAm age decelerated group (DEC).

| Characteristics                      | Total (%) | DNAmAge-ACC (N = 70) | DNAmAge-DEC (N = 318) | p* |
|--------------------------------------|-----------|----------------------|-----------------------|----|
|                                      |           |                      |                       |    |
| **Age (years)**                      |           |                      |                       |    |
|                                      | 388 (100) | 61.4 ± 12.2          | 66.0 ± 10.2           | 0.004 |
| **Fraction_Genome_Altered**         |           |                      |                       |    |
|                                      | 353 (91)  | 0.3 ± 0.2            | 0.2 ± 0.2             | 0.342 |
| **Mutation_Count**                  |           |                      |                       |    |
|                                      | 311 (90)  | 371.2 ± 650.4        | 399.5 ± 620.4         | 0.741 |
| **Stage**                           |           |                      |                       |    |
| I+II                                 | 174 (44.8)| 32 (45.7)            | 142 (44.7)            | 0.3632 |
| III+IV                               | 203 (52.3)| 38 (54.3)            | 165 (51.9)            |        |
| Missing                              | 11 (2.8)  | 0 (0)                | 11 (3.5)              | 0.3554 |
| **Race**                             |           |                      |                       |    |
| White                                | 252 (64.9)| 47 (67.1)            | 205 (52.8)            | 0.7831 |
| Others                               | 102 (26.3)| 20 (28.6)            | 82 (21.1)             |        |
| Missing                              | 34 (8.8)  | 3 (4.3)              | 31 (7.9)              |        |
| **Sex**                              |           |                      |                       |    |
| Male                                 | 244 (62.9)| 42 (60)              | 202 (63.5)            | 0.6043 |
| Female                               | 111 (28.6)| 21 (30)              | 90 (28.3)             |        |
| Missing                              | 33 (8.5)  | 7 (10)               | 26 (8.2)              |        |
| **Person_Neoplasm_Status**           |           |                      |                       |    |
| With tumor                           | 76 (19.6) | 11 (15.7)            | 65 (20.4)             | 0.0580 |
| Tumor free                           | 226 (58.2)| 41 (58.6)            | 185 (58.2)            |        |
| Missing                              | 86 (22.2) | 18 (25.7)            | 68 (21.4)             |        |
| **Overall Survival**                 |           |                      |                       |    |
| Live                                 | 237 (61.1)| 50 (71.4)            | 187 (58.8)            | 0.268 |
| Death                                | 151 (38.9)| 20 (28.6)            | 131 (41.2)            |        |
| **Disease-specific survival**        |           |                      |                       |    |
| Live                                 | 100 (25.8)| 13 (18.6)            | 87 (27.4)             |        |
| Death                                | 279 (74.7)| 56 (80.0)            | 223 (72.6)            |        |
| Missing                              | 9 (2.8)   | 1 (1.4)              | 8 (2.5)               |        |

*Fisher’s exact test for categorical data and a two-sample Mann-Whitney test for continuous data.

Continuous values are represented with mean ± SD.
the associations of DNAm age with clinical outcomes and other molecular characteristics in TCGA STAD patients.

Some previous studies suggested that a younger DNAm age in normal tissue is related to improved body health (Perna et al., 2016; Yang et al., 2016; Zhang et al., 2017). Interestingly, in this study, the epigenetic age pattern observed in normal gastric samples was disrupted in STAD samples and a younger DNAm age was related to worse prognosis of STAD patients. Additionally, compared with tumor adjacent normal tissues, the DNAm age in STAD tissues was significantly decreased which indicated that DNAm age shift in gastric cells inversely disrupted physiological epigenetic age pattern. Our analysis results were reasonable for DNAm age in normal tissue was correlated with the number of cell passages and

![Figure 4](image-url)
caused a highly heritable measure of chronological age acceleration (Horvath, 2013). Notably, subclonal evolution, formation of cancer stem cells, and somatic cell mutations during the process of tumorigenesis might impair the proliferation, propagation, and epigenetic pattern of normal cells (Chen et al., 2015; van Niekerk et al., 2017). DNAm age of tumor cells also increases with cell propagation and tumor cells with lower DNAm age have a higher cell proliferation potential, thus might grow into more aggressive cancer cells (Horvath, 2013). Function annotation analysis found that DMPs and DEGs between DNAmAge-ACC and DNAmAge-DEC groups were significantly enriched in cancer associated pathway including immune, TP53, VEGFA, and hypoxia pathway, which suggested that decreased DNAm age may affect the prognosis of STAD patients by directly activating cancer-related signaling pathways. In addition, motif enrichment and survival analysis based on DMPs showed that Sox family associated motifs and transcription factors including Sox5, Sox21, Sox7, and Sox2 were related to the prognosis of STAD patients. It is relevant to know that Sox gene family are indeed crucial as deregulation of Sox-family transcription factors can potentially lead to changes in cell fate as well as irregular cell growth (Sarkar and Hochedlinger, 2013; Kumar and Mistri, 2019). Most STAD samples in DNAmAge-ACC group showed higher mean methylation level, which may affect the binding of Sox family transcription factors to regulatory elements and irregular cell growth. The present findings are in agreement with a previous study, which reported that epigenetic age pattern was impaired in CSCC and a younger DNAm age was related to worse prognosis of CSCC patients (Lu et al., 2020). Similarly, another study focused on breast cancer found that DNAm age acceleration was significantly associated with better prognosis after adjusting for clinicopathological variables (Ren et al., 2018). Combining these studies, we believe that DNAm age shift may share some common pathogenesis in different cancers.
The immune environment in tumors plays an important role in response to therapy and prognosis in various cancer types (Thorsson et al., 2019). Immune cell infiltration such as Th2 and mast cells has been reported to be associated with the prognosis of STAD patients (Wang et al., 2020). In this study, we also found that Tgd cell, mast cell, Th2 cell, Th1 cell, and summary immune score are related to the prognosis of STAD patients. In addition, DNAm age in TCGA STAD patients was significantly positively related to the infiltration intensity of immune cells and DNAmAge-ACC group presented an immune-active pattern. Such finding was reasonable for both DNAm age acceleration and immunoactivation in STAD patients. In addition, DMPs and DEGs between DNAmAge-ACC and DNAmAge-DEC groups were significantly enriched in immune-related pathway. We, therefore, speculate that DNAm age shift affects the prognosis of STAD patients by affecting the expression of immune-related genes.

Tumor microenvironment is composed of a highly integrated ecosystem including cancer cells, infiltrating immune cells, and cancer stem cells (CSCs; Malta et al., 2018). CSCs are cancer cells that share the characteristics of normal stem cells (NSCs) and thus have the ability to give rise to all cancer cell types (Bjerkvig et al., 2005). Unlike NSCs, CSCs are considered to be responsible for carcinogenesis and maintaining cancer cell growth, and play an important role in the process of cancer metastasis and recurrence (Kabakov et al., 2020; Schulte et al., 2020). Stemness was considered as the potential for cell differentiation from the cell-of-origin and self-renewal, and was the chronic inflammation exist in the cancer microenvironment (Ma et al., 2016). As we mentioned in the previous section, DMPs and DEGs between DNAmAge-ACC and DNAmAge-DEC groups were significantly enriched in immune-related pathway. We, therefore, speculate that DNAm age shift affects the prognosis of STAD patients by affecting the expression of immune-related genes.
originally attributed to NSCs that have the potential to differentiate into various types of cells in the adult organism (Barbee and Trippodo, 1987; Lian et al., 2019). In the present study, we calculated the mRNASt (stemness) of STAD samples based on OCLR algorithm, and found that higher mRNASt was related to a better prognosis of STAD patients including OS, DSS, DFI, and PFI. In addition, compared to the DNAmAge-DEC group, mRNASt in DNAmAge-ACC group was significantly increased and was significantly positively correlated with DNAm age. Such findings were reasonable for both DNAmAge-ACC
and higher mRNAsi in STAD patients were associated with favorable prognosis. Interestingly, early study showed that the relationship between mRNAsi and OS was different across cancer-derived (Malta et al., 2018). On one hand, higher mRNAsi in adrenocortical carcinoma (ACC), kidney chromophobe (KICH), liver hepatocellular carcinoma (LIHC), and prostate adenocarcinoma (PRAD) plays a harmful role in the patient’s OS; however, higher mRNAsi in colon adenocarcinoma (COAD), glioblastoma
multiforme lower grade glioma (GB-LGG), and STAD plays a protective role in the patient’s OS (Malta et al., 2018). This phenomenon indicates that mRNAsi may be a double edged sword with various biological effects in different tumors. The association between tumor stemness signatures and adverse prognosis outcome for some cancer types, including STAD, may reflect cancer cell origins or the impact of their microenvironment. Dedifferentiated cells can arise from different sources: from progenitor cells or long lived stem cells that accumulate mutations in oncogenic pathways, or via dedifferentiation from non-stem cancer cells that convert to cancer stem cells through deregulation of developmental and/or non-developmental pathways. We speculate that the inherent stemness of cancer stem cells and dedifferentiation induced by the tumor microenvironment may be the cause of the difference in the prognosis of each tumor.

We would like to acknowledge that our present study is not devoid of limitations. First, our present study has a drawback of retrospective design with selection bias, and it is also limited to a single center (TCGA) that provided all of the STAD patient samples. Second, we simply mixed truly gastric tissue samples with two adjacent-normal gastric samples collected from TCGA STAD cohort. Due to the lack of sufficient TCGA cohort adjacent-normal gastric samples, we cannot definitively confirm whether there is a difference between adjacent-normal and normal gastric tissue. Finally, our findings will need further confirmation from other research centers and larger prospective studies for their generalizability.

CONCLUSION

In summary, this study revealed novel evidence that epigenetic clock shift was associated with canceration and all-cause mortality. DNAm age acceleration in STAD patients was associated with higher mRNAsi, immunoactivation, and favorable prognosis. DNAm age shift could be considered as a useful indicator to guide clinical prognosis assessment and be a potential therapeutic target for STAD patients. Further molecular biology experiments in vivo and in vitro are needed to investigate the mechanism of age-associated DNAm patterns in STAD. In addition, an external cohort to validate the prognosis effect of DNAm age shift is warranted.

REFERENCES

Ambatipudi, S., Horvath, S., Perrier, E., Cuenin, C., Hernandez-Vargas, H., Le Calvez-Kelm, E., et al. (2017). DNA methylome analysis identifies accelerated epigenetic ageing associated with postmenopausal breast cancer susceptibility. Eur. J. Cancer 75, 299–307. doi: 10.1016/j.ejca.2017.01.014

Aran, D., Hu, Z., and Butte, A. J. (2017). xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 18:220. doi: 10.1186/s13059-017-1349-1

Barbee, R. W., and Trippodo, N. C. (1987). The contribution of atrial natriuretic factor to acute volume natriuresis in rats. Am. J. Phys. 253, F1129–F1135. doi: 10.1152/ajprenal.1987.253.6.F1129

Bjerkvig, R., Tynes, B. B., Aboody, K. S., Nabauer, J., and Terzis, A. J. (2005). Opinion: the origin of the cancer stem cell: current controversies and new insights. Nat. Rev. Cancer 5, 899–904. doi: 10.1038/nrc1740

DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.

AUTHOR CONTRIBUTIONS

CZ, CH, and SY designed the study and research. QW, WW, JC, and DZ collected the data. ML, LL, JL, HY, and HC completed the data analysis and interpretation. CZ, CH, and QZ drafted and revised the article for important intellectual content. All authors contributed to the article and approved the submitted version.

FUNDING

This study was supported by the National Natural Science Foundation of China (30700805 and 81702325), the Sanming Project of Medicine in Shenzhen (SZSZM201911010), Research Project of Shenzhen Health Family Planning System (SZBC2018001), the Science and Technology Planning Project of Guangdong Province, China (2017A02021S014), and Medical Scientific Research Foundation of Guangdong Province, China (A2017274).

ACKNOWLEDGMENTS

We thank Mark Zheng of Department of Urology (Fujian Medical University Union Hospital) for editing the manuscript and providing statistical and bioinformatics help.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fgene.2021.563051/full#supplementary-material

Chen, H., Lin, F., Xing, K., and He, X. (2015). The reverse evolution from multicellularity to unicellularity during carcinogenesis. Nat. Commun. 6:6367. doi: 10.1038/ncomms7367

Couderc, L. J., Caubarrere, L., Oksenbergler, E., and Clauvel, J. P. (1987). Vascular malformations and hypogammaglobulinaemia. Lancet 1:385. doi: 10.1016/s0140-6736(87)91755-7

Daly, K., Ho Sui, S. J., Schriml, L. M., Drexheimer, P. J., Salomonis, N., Schlott, R., et al. (2017). Molecular, phenotypic, and sample-associated data to describe pluripotent stem cell lines and derivatives. Sci. Data 4:170030. doi: 10.1038/sdata.2017.30

Dicken, B. J., Bigam, D. L., Cass, C., Mackey, J. R., Joy, A. A., and Hamilton, S. M. (2005). Gastric adenocarcinoma: review and considerations for future directions. Ann. Surg. 241, 27–39. doi: 10.1097/01.sla.0000149300.28588.23

Elinav, E., Nowarski, R., Thaiss, C. A., Hu, B., Jin, C., and Flavell, R. A. (2013). Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat. Rev. Cancer 13, 759–771. doi: 10.1038/nrc3611
Gao, X., Colicino, E., Shen, J., Just, A. C., Nwaaji-Ewerem, J. C., Wang, C., et al. (2018). Accelerated DNA methylation age and the use of antihypertensive medication among older adults. Aging (Albany NY) 10, 3210–3228. doi: 10.18632/aging.102639

Hofstatter, E. E., Horvath, S., Dalela, D., Gupta, P., Chagpar, A. B., Wali, V. B., et al. (2018). Increased epigenetic age in normal breast tissue from luminal breast cancer patients. Clin. Epigenetics 10:112. doi: 10.1186/s13148-018-0534-8

Horvath, S. (2013). DNA methylation age of human tissues and cell types. Genome Biol. 14:R115. doi: 10.1186/gb-2013-14-10-r115

Horvath, S. (2015). Erratum to: DNA methylation age of human tissues and cell types. Genome Biol. 16:96. doi: 10.1186/s13059-015-0649-6

Jiang, Y., Xie, J., Huang, W., Chen, H., Xi, S., Han, Z., et al. (2019). Tumor immune microenvironment and chemosensitivity signature for predicting response to chemotherapy in gastric cancer. Cancer Immunol. Res. 7, 2065–2073. doi: 10.1158/2326-066X.CIR-19-0311

Kabakov, A., Yakimova, A., and Matchuk, O. (2020). Molecular chaperones in cancer stem cells: determinants of stemness and potential targets for antimtumor therapy. Cell 9:892. doi: 10.3390/cells9040892

Kresovich, J. K., Xu, Z., O’Brien, K. M., Weinberg, C. R., Sandler, D. P., and Taylor, J. A. (2019). Methylation-based biological age and breast cancer risk. J. Natl. Cancer Inst. 111, 1051–1058. doi: 10.1093/jnci/djz020

Kumar, P., and Mistri, T. K. (2019). Transcription factors in SOX family: potent regulators for cancer initiation and development in the human body. Semin. Cancer Biol. 67, 103–113. doi: 10.1016/j.semcancer.2019.06.016

Levy, T. M., Sokolov, A., Gentles, A. J., Burzykowski, T., Poisson, L., Weinstein, J. N., et al. (2018). Machine learning identifies stemness features in medulloblastoma. Mol. Oncol. 13, 2227–2245. doi: 10.1002/1878-0216.12557

Lu, X., Zhou, Y., Meng, J., Jiang, L., Gao, J., Fan, X., et al. (2020). Epigenetic age acceleration of cervical squamous cell carcinoma converged to human papillomavirus 16/18 expression, immunoaactivation, and favourable prognosis. Clin. Epigenetics 12:23. doi: 10.18632/aging.102465

Ma, H. Y., Liu, X. Z., and Liang, C. M. (2016). Inflammatory microenvironment contributes to epithelial-mesenchymal transition in gastric cancer. World J. Gastroenterol. 22, 6619–6628. doi: 10.3748/wjg.v22.i29.6619

Malta, T. M., Okongoo, S. K., Williams, L. C., Pitsinis, T., Weinberg, K. R., Wu, H. S., et al. (2015). DNA methylation signatures in peripheral blood strongly predict all-cause mortality in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

March 2021 | Volume 12 | Article 563051

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Hong, Yang, Wang, Zhang, Wu, Chen, Zhong, Li, Li, Yu, Chen, Zeng and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.